eGurukul chemotherapy handouts: A primer for medical oncology residents

Subclass or mechanism of action

Anthracycline a topoisomerase II inhibitor and DNA intercalator generates free radicals which has a class cardiotoxicity and vesicant behavior. Doxorubicin was originally isolated in the 1960s from Streptomyces peucetius var. caesius as a semisynthetic analog of daunorubicin, developed by Italian investigators at Farmitalia to broaden antitumor activity beyond leukemias.

Breast cancer adoption landmarks

NSABP B 15 established AC 60/600 every 21 days for 4 cycles as equivalent to prolonged CMF, with similar disease-free survival (DFS) and overall survival (OS), but a much shorter and more convenient course. CALGB 9741 (C9741) showed that dose dense scheduling every 14 days with granulocyte-colony-stimulating factor (G CSF) support improves DFS and OS compared with every 21 days.

Resident note

Anthracycline taxane sequences remain the backbone for high-risk early breast cancer. When choosing AC-based regimens, always balance the incremental DFS and OS benefit against long-term risks of cardiomyopathy and therapy-related myeloid neoplasms, especially in younger patients who are expected to be long-term survivors. As a reference, clinically overt congestive heart failure occurs in roughly 1–2% of patients by 300 mg/m², around 5% by 400 mg/m², and more than 15–20% by 550 mg/m² of cumulative doxorubicin equivalents in older datasets, while therapy related acute myeloid leukemia or myelodysplastic syndrome after anthracycline plus alkylator adjuvant regimens is on the order of 0.5 to 1% at 8–10 years. Several anthracycline sparing strategies are now standard comparators in early breast cancer: TC for 4 cycles (docetaxel cyclophosphamide) improved DFS and OS compared with AC for 4 cycles in US Oncology 9735, and docetaxel carboplatin trastuzumab (TCH) in BCIRG 006 achieved similar or better efficacy with less cardiac toxicity than AC followed by TH in human epidermal growth factor receptor 2 positive disease. These are the key data to quote when you justify omitting anthracyclines in suitable risk groups.

Pharmacokinetics

Hepatic metabolism; biliary excretion; cumulative, dose-related cardiomyopathy. Clearance is predominantly hepatic and exposure increases as bilirubin rises. It is 70% plasma pritein bound.

Drug Drug Interactions

Concomitant trastuzumab and prior or ongoing chest radiotherapy increase cardiotoxic risk; avoid live vaccines during periods of myelosuppression.

Resident note

Because clearance is predominantly biliary, dose adjustments should follow bilirubin and transaminase cutoffs rather than creatinine. Make it a habit to specify a hepatic dose plan at baseline and to recheck liver function tests before every cycle. Document cumulative anthracycline dose from all prior regimens in doxorubicin equivalents using standard conversion factors (for example, doxorubicin × 1, epirubicin × 0.5–0.67, daunorubicin × 0.5–0.83, idarubicin × 2–5, mitoxantrone × 2.2–4) and update this at each visit.

Adjuvant or neoadjuvant (curative intent)

AC every 21 days for 4 cycles: Doxorubicin 60 mg/m² IV day 1 + Cyclophosphamide 600 mg/m² IV day 1 every 21 days for 4 cycles. (NSABP B 15).

Key point for memory: NSABP B 15 showed no meaningful difference in DFS or OS between AC for 4 cycles and classical CMF for 6 cycles; the clinically relevant advantage was a much shorter regimen with similar cure rates.

Dose dense AC every 14 days for 4 cycles (G CSF mandatory): Doxorubicin 60 mg/m² IV day 1 + Cyclophosphamide 600 mg/m² IV day 1 every 14 days for 4 cycles, with pegfilgrastim support, typically followed by paclitaxel (CALGB 9741).

Remember that dose dense scheduling produced roughly a 26% relative reduction in recurrence (DFS hazard ratio about 0.74) and a 31% relative reduction in mortality (OS hazard ratio about 0.69) compared with every 21-day scheduling.

EC or FEC variants: A common regimen is EC 90/600 every 21 days for 4 cycles.

Metastatic disease

Components of FAC or FEC, or sequential anthracycline then taxane, depending on disease biology, prior exposure, and cardiac reserve.

Resident note

In metastatic disease, reserve further anthracycline exposure for patients without prior adjuvant anthracycline or with long treatment-free intervals and avoid exceeding lifetime cumulative dose once effective non-anthracycline options are available. Rechallenge with conventional doxorubicin or switch to liposomal doxorubicin can be considered in metastatic breast cancer if baseline left ventricular ejection fraction (LVEF) is preserved and the doxorubicin equivalent dose is still below the accepted threshold, but this should be a conscious choice after comparing competing options such as taxanes, capecitabine, endocrine therapy plus targeted agents, or antibody drug conjugates.

NSABP B 15

AC 60/600 every 3 weeks for 4 cycles versus classical CMF for 6 cycles: no difference in 3-year DFS or OS; AC was operationally preferable due to shorter duration and fewer visits. For viva purposes, it is enough to remember that the absolute differences in DFS and OS were well under 2%, supporting equivalence.

CALGB 9741

Dose dense AC followed by paclitaxel every 2 weeks with filgrastim support improved DFS (risk ratio 0.74, P = 0.010) and OS (risk ratio 0.69, P = 0.013) compared with every 3-week dosing.

Resident note

Benefit from dose-dense AC is greatest in node-positive, higher-risk biology. In lower-risk hormone receptor-positive disease, non-anthracycline regimens such as TC may provide comparable outcomes with less cardiac risk. As a simple anchor, TC for 4 cycles improved 5-year DFS by about 5–6% over AC for 4 cycles in US Oncology 9735, while BCIRG 006 showed that the anthracycline-free TCH regimen gives similar invasive DFS to AC, followed by TH but with fewer symptomatic cardiac events and fewer cases of therapy-related leukemia. These trials are the pivot for de-escalating anthracyclines in genomically or clinically lower-risk patients.

Common breast doses

AC every 21 or 14 days: Doxorubicin 60 mg/m² IV day 1 (administer before cyclophosphamide on the same day).

Preparation or diluent (conventional doxorubicin HCl)

Dilute in 0.9% sodium chloride or 5% dextrose. Protect from light after preparation. Manufacturers typically direct use within 1 h for diluted product.

Infusion time and administration

Give through a free-flowing line of 0.9% sodium chloride or D5W; usual IV push or short infusion 2–15 min (or over 5–15 min as per regimen). Avoid small, fragile peripheral veins because of vesicant risk. In VAC regimen it is given over 6 hours.

Stability after dilution

Use within 1 h after dilution. Some product information documents chemical or physical stability up to 7 days at 2–8°C or at room temperature at 0.5 mg/mL. Microbiological shelf life is 24 h unless aseptically compounded under validated sterile conditions.

Vesicant classification and extravasation management

Doxorubicin is a vesicant. Dexrazoxane protocol: Start within 6 h of suspected extravasation; Day 1: 1000 mg/m², Day 2: 1000 mg/m², Day 3: 500 mg/m², each over 1–2 h; avoid concurrent dimethyl sulfoxide; reduce dexrazoxane dose by 50% if estimated Glomerular Filtration Rate (eGFR) is <40 mL/min.

Resident note

In day care oncology practice, clearly label anthracycline syringes or minibags and use a documented vesicant checklist at chairside (blood return, line position, patient counseling on burning or pain) before each push. If day care is crowded, standardizing a brief “vesicant timeout” where the nurse and Resident confirm vein, backflow, and patient education just before doxorubicin administration can significantly reduce preventable injuries.

Emetogenicity

AC is high emetic risk. A standard regimen, as per many protocols, is an NK1 receptor antagonist (for example, netupitant) plus palonosetron plus dexamethasone on day 1, with or without continuation of dexamethasone on days 2 and 3 as per institutional protocol.

Major adverse events

Myelosuppression, nausea and vomiting, alopecia, mucositis, cardiotoxicity. Rates vary by regimen, dose intensity, and patient factors. There can be complete alopecia (up to 100%), regrowth occurs 2-3 months after discontinuing doxorubicin therapy.

Cardiotoxicity

A commonly used definition is a fall in LVEF >10% to below 45%. Risk increases with cumulative dose. Historical lifetime cumulative dose limits are approximately 400–450 mg/m². For teaching, quote two anchor points: Clinically important cardiotoxicity is uncommon below 300 mg/m², begins to rise around 400 mg/m², and increases sharply beyond 450– 500 mg/m², especially in the presence of other risk factors. These include previous radiation to chest, heart disease, advanced age, liver disease, concurrent chemotherapy like paclitaxel, cyclophosphamide, hyperthermia.

Monitoring thresholds

Typical thresholds before AC are an absolute neutrophil count of at least 1.5 × 10⁹/L and platelets at least 100 × 10⁹/L.

FN risk and G CSF

Dose-dense AC requires primary G CSF prophylaxis. For every 21-day AC, consider primary G CSF when the estimated febrile neutropenia risk, based on regimen and patient factors, is at least 20%.

Resident note

High-risk groups for early cardiotoxicity include prior mediastinal radiation, pre-existing reduced LVEF, poorly controlled hypertension, older age, and planned sequential trastuzumab. Involve cardio oncology early for these patients with baseline global longitudinal strain (GLS) and troponin where available. As a practical rule, seek cardio oncology input if baseline LVEF is below about 55%, GLS is less negative than roughly minus 18%, or baseline high-sensitivity troponin is already above the laboratory upper limit of normal before starting anthracyclines.

Hepatic impairment

Dose is reduced according to label or institutional policy because of biliary excretion. To avoid duplication, anchor all hepatic adjustments to a single scheme: for example, give 75% of the dose if ALT or AST is 2–3 times the upper limit of normal, 50% if ALT or AST is more than 3 times the upper limit of normal or bilirubin is 20–50 µmol/L, 25% if bilirubin is 51–85 µmol/L, and withhold doxorubicin if bilirubin is higher. Always cross-check with your local protocol.

Renal impairment

Conventional doxorubicin is usually given at full dose across eGFR strata in AC protocols; monitor closely in patients with severe renal dysfunction, as supportive care may be more complex.

Elderly or frail patients

Higher cardiotoxic and febrile neutropenia risk. Prefer every 21-day schedules or carefully selected dose-dense regimens with robust growth factor support and early cardio oncology involvement.

Pregnancy and lactation

Contraindicated in breastfeeding. Avoid in pregnancy except for urgent, life-saving indications in selected trimesters, and only after multidisciplinary discussion.

Resident note

In very young women, always document fertility counselling and ovarian protection strategy before starting anthracyclines, as cumulative exposure often precedes alkylator or taxane therapy. Record whether gonadotropin-releasing hormone agonist, embryo or oocyte preservation, or no fertility intervention was chosen; this becomes important when they are present years later with metastatic disease or wish to conceive.

Antiemetic planning

Treat AC as high emetic risk: NK1 receptor antagonist + 5 HT3 receptor antagonist + dexamethasone on day 1; continue dexamethasone with or without other agents on days 2 and 3 according to local policy.

G CSF strategy

Mandatory for dose dense AC every 14 days; consider for every 21-day AC if the combined regimen and patient level risk for febrile neutropenia is at least 20%.

Baseline workup

CBC, renal and hepatic function, and baseline LVEF (echocardiogram or MUGA) before anthracycline initiation. Schedule interval LVEF monitoring based on cumulative dose and clinical risk.

Sequence on AC day

Doxorubicin is given first, followed by cyclophosphamide. Taxane is added in subsequent cycles or visits as per protocol.

Setting of care

AC is standard in day care; inpatient administration is reserved for patients requiring continuous infusions or for management of complications.

Cardioprotection and monitoring

Dose dense scheduling is now coupled with routine growth factor support. Cardio oncology surveillance using GLS and troponin is evolving to optimize early risk detection. Echo-based strain imaging is increasingly used; a relative GLS drop of more than 15% from baseline or an absolute fall in LVEF of more than 10% to below 53% is often taken as a signal to intensify cardioprotective therapy or interrupt anthracyclines. Serial high-sensitivity troponin elevations above the laboratory upper limit of normal during treatment also predict later cardiomyopathy and should prompt early cardio-oncology review.

Formulation strategies

Liposomal doxorubicin reduces cardiotoxicity compared with conventional doxorubicin and is used in selected contexts but is not standard for the AC backbone in adjuvant breast cancer. You should not substitute liposomal for conventional doxorubicin on a milligram-for-milligram basis into the AC backbone, because adjuvant efficacy data are based on conventional formulations. Liposomal preparations are best reserved for metastatic or palliative settings or for patients in whom further anthracycline exposure is considered important but baseline cardiac risk is high.

Cardioprotective co-medication

Drugs such as atorvastatin, ramipril, and metoprolol have shown benefit in reducing cardiac toxicity in selected trials. Randomized studies such as PRADA and MANTICORE have demonstrated that prophylactic angiotensin-converting enzyme inhibitors or beta blockers can limit mean LVEF decline by roughly 3–4% compared with placebo during anthracycline or anthracycline plus trastuzumab therapy, while observational series with statins suggest a similar magnitude of protection. For residents, it is enough to remember that combined neurohormonal blockade and statins can modestly attenuate LVEF drop and are increasingly used in high-risk patients.

Resident note

As liposomal preparations and cardioprotective co-medications become more accessible, residents should be comfortable calculating anthracycline equivalent dosing across formulations to avoid exceeding total lifetime thresholds. Whenever cardioprotective strategies are used, document both the oncology intent (curative versus palliative) and the cardiac plan (agents, doses, and monitoring schedule) so that subsequent teams can continue the same approach consistently.

Vesicant precautions

Strict IV access checks. If extravasation is suspected, stop immediately, aspirate, elevate, apply cold compresses, and start dexrazoxane within 6 h using the 1000, 1000, 500 mg/m² day 1–3 protocol (with 50% dose reduction if eGFR is less than 40 mL/min).

High emetic risk prophylaxis is mandatory. Label-based stability after dilution is restrictive (use within 1 h), but local sterile compounding policies may permit longer hold times at specific concentrations and temperatures; always follow institutional guidance.

Resident note

Always write the cumulative anthracycline dose clearly on the first page of the paper file or in the electronic record and update it at each cycle. Once patients cross about 300 mg/m² in doxorubicin equivalents, lower the threshold for cardio-oncology referral, interval echocardiography, and consideration of non-anthracycline options if further chemotherapy is planned. A simple visual cue, such as a prominent flag in the electronic record or a colored sticker once the cumulative dose exceeds 300 mg/m², can prevent inadvertent overdosing in a busy clinic.